// App-Quantinova.ai

TPS9107 : A phase II multicenter, randomized, placebo-controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC).

Researchers

Presenter

  • Benjamin Philip Levy

Principal Investigators

  • Giuseppe Giaccone

  • Benjamin Besse

  • Damir Begic

  • Xiaoling Wu

  • Abderrahim Fandi

  • Luis Paz-Ares

Medical Centers

  • Mount Sinai Health Systems, New York, NY

  • Georgetown University, Washington, DC

  • Dpt of Medical Oncology, Gustave Roussy, Villejuif, France

  • Celgene Corporation, Summit, NJ

  • Celgene, Summit, NJ

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

Locations

  • United States

  • Spain

  • France

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Anaplastic lymphoma Kinase

  • Programmed death-ligand 1

  • Epidermal growth factor receptor

  • tumor-infiltrating lymphocytes

  • DNA methylation

Drug/Treatment

  • Pembrolizumab

  • Vidaza

  • CC-486

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • II

Study Id's

  • NCT02546986

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved